Información del artículo
Resumen
Analizamos la validez del cribado bioquímico delsegundo trimestre instaurado en nuestro hospital enlos primeros 10 meses desde su establecimiento. Losresultados obtenidos demuestran un alto índice de falsos positivos (el 14, 47% de manera global; el 9, 16%en pacientes menores de 35 años, y el 47,61% en pacientes de 35 años o más), lo que hace replantearse laadquisición de un nuevo programa de laboratoriodonde se incluyan marcadores sanguíneos más específicos con la finalidad de mejorar esta prueba.
summary
We have analyzed the validity of second trimester biochemical screening during the 10 months since its establishment. The results obtained showed a high level of false positive rates (14.47% overall, 9.16% under 35 years of age, and 47.61% for 35 years or over), which has led us to look for a new laboratory kit which includes more specific blood markers in order to improve this test.
El Texto completo está disponible en PDF
Bibliografía
[1.]
NJ Wald, A Kennard, A Hackshaw, A. McGuire.
Antenatal screening for Down’s syndrome.
J Med Screen, 4 (1997), pp. 181-246
[2.]
B Norgaard-Pederson, SO Larsen, J Arends, B Svenstrup, A. Tabor.
Serum markers in screening for Down’s syndrome.
Clin Genet, 37 (1990), pp. 35-43
[3.]
K Spencer, EJ Coombes, AS Mallard, AM. Ward.
Free beta human choriogonadotropin in Down’s syndrome screening: a multicentre study of its rol compared with other biochemical markers.
Ann Clin Biochem, 29 (1992), pp. 506-518
[4.]
C Lemay, N Roussel-Mizon, F Thepot, G. Desmet.
Maternal serum screening for fetal Down’s syndrome a retrospective study.
Clin Chim Acta, 238 (1995), pp. 151-162
[5.]
T Chard, MC. Macintosh.
Screening for Down’s syndrome.
J Perinat Med, 23 (1995), pp. 421-436
[6.]
NJ Wald, A Kennard, A Hackshaw, A. McGuire.
Antenatal screening for Down’s syndrome.
J Med Screen, 5 (1998), pp. 166
[7.]
NJ Wald, L George, D Smith, JW Densem, K. Petterson.
Serum screening for Down’s syndrome between 8 and 14 weeks of pregnancy.
Br J Obstet Gynaecol, 103 (1996), pp. 407-412
[8.]
E Berry, DA Aitken, JA Crossley, JN Macri, JN. Connor.
Screening for Down’s syndrome: changes in marker levels and detection rates between first and second trimesters.
Br J Obstet Gynaecol, 104 (1997), pp. 811-817
[9.]
E Casals, C Aibar, JM Martínez, A Borrell, A Soler, J Ojuel, et al.
First trimester biochemical markers for Down’s syndrome.
Prenat Diagn, 19 (1999), pp. 8-11
[10.]
PP Pandya, C Santiago, RJ Snijders, KH. Nicolaides.
First trimester fetal nuchal translucency.
Curr Opin Obstet Gyne-col, 7 (1995), pp. 95-102
[11.]
B Thilaganathan, A Slack, NC. Wathen.
Effect of first trimester nuchal translucency on second trimester maternal serum biochemical screening for Down’s syndrome.
Ultrasound Obstet Gynecol, 10 (1997), pp. 261-264
[12.]
M Christiansen, SO Larsen, B. Norgaard-Pedersen.
Serum screening of pregnant women reveals Down’s syndrome.Analysis of biochemical.
Lakartidningen, 94 (1997), pp. 4898-4902
[13.]
S Yagel, EY Anteby, D Holoner-Celnikier, I Ariel, T Chaap, Neriah Z. Ben.
The rol of midtrimester targeted fetal organ screening combined with the triple test and maternal age in the diagnosis of trisomy 21: a retrospective study.
Am J Obstet Gynecol, 178 (1998), pp. 40-44
[14.]
LS. Chitty.
Antenatal screening for aneuploidy.
Curr Opin Obstet Gynecol, 10 (1998), pp. 916
[15.]
DA Nyberg, VL. Souter.
Sonographic markers of fetal aneu-ploidy.
Clin Perinatol, 27 (2000), pp. 761-789
[16.]
GD Michailidis, K Spencer, DL. Economides.
The use of nuchal translucency measurement and second trimester biochemical markers in screening for Down’s syndrome.
Br J Obstet Gynaecol, 108 (2001), pp. 1047-1052
[17.]
VL Souter, DA Nyberg, A El-Bastawissi, A Zebelman, F Luthhardt, DA. Luthy.
Correlation of ultrasound findings and biochemical markers in thesecond trimester of pregnancy in fetuses with trisomy 21.
Prenat Diagn, 22 (2002), pp. 175-182
[18.]
P Rozenberg, L Malagrida, H Cuckle, I Durand-Zaleski, I Ni-sand, F Audibert, et al.
Down’s syndrome screening with nuchal translucency at 12(+0)-14(+0) weeks and maternal serum at 14(+1)-17(+0) weeks: a prospective study.
Human Reprod, 17 (2002), pp. 1093-1098
[19.]
Kaisenberg CS Von, A Gasiorek-Wiens, M Bielicki, F Bahl-mann, H Meyberg, A Kossakiewicz, et al.
Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum, biochemistry at 11-14 weeks: a German multicenter study.
J Matern Fetal Neonatal Med, 12 (2002), pp. 8994
[20.]
K Spencer, HS. Cuckle.
Screening for chromosomal anomalies in the first trimester: does repeat maternal serum screening improve detection rates?.
Prenat Diagn, 22 (2002), pp. 903-906
[21.]
PA Benn, LM Kaminsky, J Ying, AF Borgida, JF. Egan.
Combined second trimester biochemical and ultrasound screening for Down’s syndrome.
Obstet Gynecol, 100 (2002), pp. 1168-1176
[22.]
JM. Last.
Diccionario de epidemiología moderna.
[23.]
L Law, T Lau, T Fung, MS Rogers, M. Hjelm.
Maternal serum screening for Down’s syndrome in a teaching hospital in Hong Kong.
Chin Med J, 112 (1999), pp. 754-757
[24.]
A Fortuny, E. Casals.
Triple screening en sangre materna.Bases, indicaciones y resultados.
Progr Diagn Prenatol, 6 (1994), pp. 442-449
[25.]
C Benattar, F Audibert, J Taieb, Y Ville, A Roberto, A Lin-denbaum, et al.
Efficiency of ultrasound and biochemical markers for Down’s syndrome risk screening.
Fetal Diagn Ther, 14 (1999), pp. 112-117
[26.]
K. Spencer.
Second trimester prenatal screening for Down’s syndrome and the relationship of maternal serum biochemical markers to pregnancy complications with adverse outcome.
Prenat Diagn, 20 (2000), pp. 652-656
[27.]
JA Crossley, DA Aitken, E Berry, JM. Connor.
Impact of a regional screening programme using maternal serum alpha fetoprotein (AFP) and human chorionic gonadotrophin (hCG) on the birth incidence of Down’s syndrome in the west of Scotland.
J Med Screen, 1 (1994), pp. 180-183
[28.]
C Lemay, N Rousel-Mizon, F Thepot, G. Desmet.
Maternal serum screening for fetal Down’s syndrome, a retrospective study.
Clin Chim Acta, 238 (1995), pp. 151-162
[29.]
S Canini, F Prefumo, L Famularo, PL Venturini, V Palazzese, P. De Biasio.
Comparison of first trimester, second trimester and integrated Down’s syndrome screening results in unaffected pregnancies.
Clin Chem Lab Med, 40 (2002), pp. 600-603
[30.]
M Perona, G Mancini, D Dall’Amico, V Guaraldo, A. Influence of smoking habits on Down’s syndrome risk evaluation at mid trimester through biochemical screening. Carbonara.
Int J Clin Lab Res, 28 (1998), pp. 179-182
[31.]
O Torok, L Veress, M Szabo, I Zsupan, Z Buczko, A Bolodar, et al.
Biocemical and ultrasonic screening of chromosomal aneuploidies in the second trimester of pregnancy.
OrvHetil, 138 (1997), pp. 123-127
[32.]
MI Evans, JE O’Brien, A. Johnson.
Screening for aneuploidy.
Curr Opin Obstet Gynecol, 11 (1999), pp. 115-118
[33.]
K Spencer, CE Spencer, M Power, C Dawson, KH. Nicolaides.
Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience.
Br J Obstet Gynaecol, 110 (2003), pp. 281-286
[34.]
JT Liu, N Hao, NH Sol, FY Wang, YH Xu, MI Gai, al. et.
Screening by maternal serum markers for Down’s syndrome.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 25 (2003), pp. 156-159
Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados
